

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CONJUPRO BIOTHERAPEUTICS, INC.,
PETITIONER,
V.
ASCLETIS PHARMA CHINA CO. LTD.,
PATENT OWNER.

CASE NO. PGR2025-00057
PATENT NO. 12,234,236
TITLE: GLP-1R AGONIST AND THERAPEUTIC METHOD THEREOF

PETITIONER'S REQUEST FOR ORAL ARGUMENT

Pursuant to the December 22, 2025, Scheduling Order (Paper 17) and 37 C.F.R. § 42.70(a), Petitioner Conjupro Biotherapeutics, Inc. (“Petitioner”), respectfully requests oral argument in the above-referenced proceeding. The oral argument is currently scheduled for August 31, 2026. (Paper 17 at 14.)

Petitioner requests an in-person hearing to be held in a Patent Trial and Appeal Board hearing room located at the USPTO’s headquarters in Alexandria, Virginia. The Parties have met and conferred, and Patent Owner Ascleitis Pharma China Co. Ltd. (“Patent Owner”) has indicated that it will seek to have the hearing held at the San Jose, CA Regional Office. However, 2-3 of Petitioner’s counsel likely to attend the hearing are located on the East Coast and none are located on the West Coast. In addition, Patent Owner has indicated that it will likely have at least one counsel from the East Coast and one from the West Coast in attendance. Finally, Petitioner understands that the Administrative Law Judges are located across the country and can appear remotely. Because both parties have counsel from the East Coast likely to attend and the majority of counsel likely to attend are from the East Coast, Petitioner believes holding the hearing at the USPTO’s headquarters in Alexandria, Virginia will be, on balance, more economical and efficient for all involved.

Petitioner requests that each side receive 60 minutes to address any issues raised in the Papers, for a total of a 120-minute hearing. Patent Owner has indicated it agrees to this proposal. Petitioner requests the opportunity to reserve a portion of its time for rebuttal.

Petitioner requests the opportunity to address all issues raised in the Papers, including:

- The obviousness of claims 1-9, 12-17, and 21-24 of U.S. Patent No. 12,234,236 in view of the asserted art;
- Patent Owner's failure to present evidence of secondary considerations that would render any claim non-obvious;
- Any other motions or issues that remain pending at the time of the hearing, including any motions to exclude evidence and responses thereto;
- Any issues raised by Patent Owner in its request for oral argument; and
- Any issues raised by the Board during the oral argument.

Petitioner also requests that both (1) a projector with a laptop connector and audio capabilities and (2) an overhead projector ("Elmo") be available for use at oral argument to display demonstratives and/or exhibits.

Respectfully submitted,

Dated: July 20, 2026

By: /s/ Lukas D. Toft
Lukas D. Toft (Reg. No. 75,311)
FOX ROTHSCHILD LLP
33 South 6th Street, Suite 3600
Minneapolis, MN 55402
Telephone: (612) 607-7336
Facsimile: (612) 607-7100
ltoft@foxrothschild.com

Joe Chen, Ph.D. (Reg. No. 70,066)
FOX ROTHSCHILD LLP
212 Carnegie Center, Suite 400
Princeton, NJ 08540
Telephone: (609) 844-3024
Facsimile: (609) 896-1469
joechen@foxrothschild.com

Howard S. Suh (*pro hac vice*)
Fox Rothschild LLP
101 Park Avenue, 17th Floor
New York, NY 10178
Telephone: (212) 878-7914
Facsimile: (212) 692-0940
hsuh@foxrothschild.com

**Attorneys for Petitioner Conjupro
Biotherapeutics, Inc.**

CERTIFICATE OF SERVICE

Pursuant to 37 CFR § 42.6(e), the undersigned hereby certifies that on July 20, 2026, the foregoing Petitioner's Request for Oral Argument was served via email, as authorized by the Patent Owner, at the following email addresses:

Geoffrey D. Biegler
gbiegler@cooley.com

Isha Agarwal
iagarwal@cooley.com

Tae Yeon Zoe Kim
Zoe.kim@cooley.com

W. Chad Shear
Cshear@cooley.com

Dated: July 20, 2026

/s/ Luke Toft
Lukas D. Toft (Reg. No. 75,311)
Counsel for Petitioner